These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 116301)

  • 1. Studies on some possible biochemical treatments of primary hyperoxaluria.
    Watts RW; Chalmers RA; Gibbs DA; Lawson AM; Purkiss P; Spellacy E
    Q J Med; 1979 Apr; 48(190):259-72. PubMed ID: 116301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The urinary response to an oral oxalate load in recurrent calcium stone formers.
    Krishnamurthy MS; Hruska KA; Chandhoke PS
    J Urol; 2003 Jun; 169(6):2030-3. PubMed ID: 12771711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of dietary changes on urinary oxalate excretion and calcium oxalate supersaturation in patients with hyperoxaluric stone formation.
    Penniston KL; Nakada SY
    Urology; 2009 Mar; 73(3):484-9. PubMed ID: 19118878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pyridoxine can normalize oxaluria in idiopathic renal lithiasis].
    Jaeger P; Portmann L; Jacquet AF; Burckhardt P
    Schweiz Med Wochenschr; 1986 Dec; 116(50):1783-6. PubMed ID: 3798070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxalate metabolism in renal stone disease with special reference to calcium metabolism and intestinal absorption.
    Lindsjö M
    Scand J Urol Nephrol Suppl; 1989; 119():1-53. PubMed ID: 2669121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 'Enteral' hyperoxaluria. Effect of cholestyramine, calcium, neomycin, and bile acids on intestinal oxalate absorption in man.
    Caspary WF; Tönissen J; Lankisch PG
    Acta Hepatogastroenterol (Stuttg); 1977 Jun; 24(3):193-200. PubMed ID: 883468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to a physiologic dose of pyridoxine in type I primary hyperoxaluria.
    Yendt ER; Cohanim M
    N Engl J Med; 1985 Apr; 312(15):953-7. PubMed ID: 3974685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Studies of urinary risk factors in urolithiasis].
    Ebisuno S; Kitagawa M; Morimoto S; Miyazaki Y; Minakata S; Yasukawa S; Fukatani T; Ohkawa T
    Hinyokika Kiyo; 1985 Jan; 31(1):1-15. PubMed ID: 3993484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absorptive hyperoxaluria: a new clinical entity--successful treatment with hydrochlorothiazide.
    Yendt ER; Cohanim M
    Clin Invest Med; 1986; 9(1):44-50. PubMed ID: 3955921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of pyridoxine supplementation on recurrent stone formers.
    Murthy MS; Farooqui S; Talwar HS; Thind SK; Nath R; Rajendran L; Bapna BC
    Int J Clin Pharmacol Ther Toxicol; 1982 Sep; 20(9):434-7. PubMed ID: 7141762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New aspects in the treatment of oxalate lithiasis (author's transl)].
    Hautmann R; Hering FJ; Terhorst B; Lutzeyer W
    Urologe A; 1976 Jul; 15(4):148-52. PubMed ID: 960323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of verapamil on urinary calcium and oxalate excretion in renal stone formers].
    Iguchi M; Ikegami M; Kiwamoto H; Umekawa T; Ishikawa Y; Kohri K; Kurita T
    Hinyokika Kiyo; 1993 May; 39(5):425-31. PubMed ID: 8322624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Renal oxalate excretion following oral oxalate load in patients with urinary calculus disease and healthy controls].
    Ebisuno S; Morimoto S; Yoshida T; Fukatani T; Yasukawa S; Okawa T
    Hinyokika Kiyo; 1986 Dec; 32(12):1773-9. PubMed ID: 3825824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of calcium, aluminium, magnesium and cholestyramine on hyperoxaluria in patients with jejunoileal bypass.
    Nordenvall B; Backman L; Larsson L; Tiselius HG
    Acta Chir Scand; 1983; 149(1):93-8. PubMed ID: 6837229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperoxaluria in idiopathic calcium nephrolithiasis--what are the limits?
    Osther PJ
    Scand J Urol Nephrol; 1999 Dec; 33(6):368-71. PubMed ID: 10636575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapeutic effect of pyridoxine and succinimide in the treatment of a patient with primary hyperoxaluria].
    Jerez E; Rapado A
    Arch Esp Urol; 1986 May; 39(4):279-82. PubMed ID: 3740976
    [No Abstract]   [Full Text] [Related]  

  • 17. [24-hour urinary oxalate excretion in healthy children and in children with calcium urolithiasis].
    Sikora P; Bieniaś B; Wawrzyszuk M; Zajaczkowska M
    Pol Merkur Lekarski; 2008; 24 Suppl 4():76-9. PubMed ID: 18924510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of pyridoxine on oxalate dynamics in three cases of primary hyperoxaluria (with glycollic aciduria).
    Watts RW; Veall N; Purkiss P; Mansell MA; Haywood EF
    Clin Sci (Lond); 1985 Jul; 69(1):87-90. PubMed ID: 4064559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hyperoxaluria and renal calculi].
    Buño Soto A; Torres Jiménez R; García Puig J; Mateos Antón F
    Arch Esp Urol; 1996 Sep; 49(7):707-26. PubMed ID: 9020008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absorptive hyperoxaluria leads to an increased risk for urolithiasis or nephrocalcinosis in cystic fibrosis.
    Hoppe B; von Unruh GE; Blank G; Rietschel E; Sidhu H; Laube N; Hesse A
    Am J Kidney Dis; 2005 Sep; 46(3):440-5. PubMed ID: 16129205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.